Based on our results, it will be interesting to investigate whether similar roles exist for endogenous tumor-associated CS-E molecules in Wnt/beta-catenin signaling, Collagen I expression, and breast cancer progression in vivo, and to investigate a potential therapeutic use of CS-E as an inhibitor of the pro-tumorigenic Wnt/beta-catenin/Collagen I pathway in breast cancer. This evidence concerns the gene CTNNB1 and breast carcinoma.